MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide

Molecular Cancer Therapeutics
Oihane EriceImanol Arozarena

Abstract

Melanoma and other solid cancers are frequently resistant to chemotherapies based on DNA alkylating agents such as dacarbazine and temozolomide. As a consequence, clinical responses are generally poor. Such resistance is partly due to the ability of cancer cells to use a variety of DNA repair enzymes to maintain cell viability. Particularly, the expression of MGMT has been linked to temozolomide resistance, but cotargeting MGMT has proven difficult due to dose-limiting toxicities. Here, we show that the MGMT-mediated resistance of cancer cells is profoundly dependent on the DNA repair enzyme PARP. Both in vitro and in vivo, we observe that MGMT-positive cancer cells strongly respond to the combination of temozolomide and PARP inhibitors (PARPi), whereas MGMT-deficient cells do not. In melanoma cells, temozolomide induced an antiproliferative senescent response, which was greatly enhanced by PARPi in MGMT-positive cells. In summary, we provide compelling evidence to suggest that the stratification of patients with cancer upon the MGMT status would enhance the success of combination treatments using temozolomide and PARPi.

References

Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·C LengauerB Vogelstein
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R MiddletonN Thatcher
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm RansonMark R Middleton
Sep 28, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Francesco MarchesiLiana De Vecchis
Oct 31, 2007·British Journal of Cancer·N M MhaidatP Hersey
Feb 5, 2008·British Medical Bulletin·Barbara VerbeekGeoffrey P Margison
May 14, 2008·British Journal of Cancer·O A KhanM R Middleton
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruth PlummerHilary Calvert
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew H KulkeMark S Redston
Sep 29, 2009·Critical Reviews in Oncology/hematology·Roger MouawadDavid Khayat
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joann P PalmaCherrie K Donawho
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amanda J WatsonMark R Middleton
Nov 17, 2010·Genes & Development·Thomas KuilmanDaniel S Peeper
May 18, 2011·Oncogene·I ArozarenaC Wellbrock
May 24, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Poulam M PatelUNKNOWN EORTC Melanoma Group
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Apr 6, 2012·Current Opinion in Oncology·Bristi BasuJohann S de Bono
May 15, 2012·The Lancet Oncology·Wolfgang WickUNKNOWN NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society
Aug 23, 2012·Journal of Biomedicine & Biotechnology·Razmik MirzayansDavid Murray
Sep 26, 2012·BMJ Case Reports·Johan A F KoekkoekMartin J B Taphoorn
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Oct 13, 2012·Expert Reviews in Molecular Medicine·Sarah Belden, Keith T Flaherty
Dec 20, 2012·Journal of the National Cancer Institute·Michael P SmithClaudia Wellbrock
Jun 19, 2013·Nature Cell Biology·Juan Carlos AcostaJesús Gil
Nov 15, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-M LeeE C Kohn
Dec 21, 2013·Molecular Cancer Therapeutics·Junko MuraiYves Pommier
Feb 15, 2014·World Journal of Clinical Oncology·Wei ZhuPing Liu
May 20, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shiv K GuptaJann N Sarkaria
Jun 20, 2014·Molecular Cancer·Imanol ArozarenaClaudia Wellbrock
Jul 30, 2014·Cell Reports·Anna ChapmanAdam Hurlstone
Aug 1, 2014·The Lancet Oncology·Michael WellerUNKNOWN European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma

❮ Previous
Next ❯

Citations

Nov 23, 2015·Molecular Cell·Mark J O'Connor
Feb 12, 2017·Cell Biology and Toxicology·Wan-Xin PengAi-Hua Gong
Nov 29, 2015·Journal of the National Cancer Institute·Shiv K GuptaJann N Sarkaria
Aug 17, 2019·Cancer Discovery·Anna F FaragoBenjamin J Drapkin
Dec 29, 2020·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Antonio ViúdezAna De Jesús Acosta
Feb 26, 2021·Frontiers in Pharmacology·Lan-Ya LiYan Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.